Viral Hepatitis

You have full text access to this OnlineOpen article

Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial†‡§

  1. Zachary D. Goodman1,‖,*,
  2. Anne M. Stoddard2,
  3. Herbert L. Bonkovsky3,¶,
  4. Robert J. Fontana4,
  5. Marc G. Ghany5,
  6. Timothy R. Morgan6,8,
  7. Elizabeth C. Wright7,
  8. Elizabeth M. Brunt9,
  9. David E. Kleiner10,
  10. Mitchell L. Shiffman11,
  11. Gregory T. Everson12,
  12. Karen L. Lindsay13,
  13. Jules L. Dienstag14,15,
  14. Chihiro Morishima16,
  15. HALT-C Trial Group

Article first published online: 5 AUG 2009

DOI: 10.1002/hep.23211

Issue

Hepatology

Hepatology

Volume 50, Issue 6, pages 1738–1749, December 2009

Additional Information

How to Cite

Goodman, Z. D., Stoddard, A. M., Bonkovsky, H. L., Fontana, R. J., Ghany, M. G., Morgan, T. R., Wright, E. C., Brunt, E. M., Kleiner, D. E., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Dienstag, J. L., Morishima, C. and HALT-C Trial Group (2009), Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. Hepatology, 50: 1738–1749. doi: 10.1002/hep.23211

Author Information

  1. 1

    Armed Forces Institute of Pathology, Division of Hepatic Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC

  2. 2

    New England Research Institutes, Watertown, MA

  3. 3

    Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT

  4. 4

    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI

  5. 5

    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  6. 6

    Division of Gastroenterology, University of California Irvine, Irvine, CA

  7. 7

    Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  8. 8

    Gastroenterology Service, VA Long Beach Healthcare System, Long Beach, CA

  9. 9

    Department of Pathology and Immunology, Washington University, St. Louis, MO

  10. 10

    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  11. 11

    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA

  12. 12

    Section of Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO

  13. 13

    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA

  14. 14

    Gastrointestinal Unit (Medical Services), Massachusetts General Hospital, Boston, MA

  15. 15

    Department of Medicine, Harvard Medical School, Boston, MA

  16. 16

    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA

  1. Carolinas Medical Center, Charlotte, NC

  1. ‖

    fax: 804-545-9701.

*American International Pathology Laboratories, 8403 Colesville Road, Silver Spring, MD 20910

  1. †

    The opinions and assertions expressed in this study are the private views of the authors and do not represent the views of the National Center for Research Resources, the National Institutes of Health, the Department of the Army, or the Department of Defense.

  2. ‡

    Potential conflict of interest: Dr. Goodman received grants from Schering-Plough, Novartis, and Pharmasset. Dr. Bonkovskyi is a consultant for and advises Boehringer-Ingelheim and Novartis. He also advises and is on the speakers' bureau of Lunbeck Pharma. He received grants from Hoffmann-LaRoche, Merck, and Vertex. Dr. Fontana is on the speakers' bureau of Roche. Dr. Lindsay received grants from Schering-Plough, Valeant, Vertex, and Wyeth. She is also a consultant for and advises Bristol-Myers Squibb, Clinical Care Options, Kendle International, King, Peregrine, Roche Diagnostics, Valeant, Zymogenetics. She received grants from, is a consultant for, and advises, Hoffmann-LaRoche, Human Genome Sciences, and Idenix Pharmaceuticals. Dr. Morgan is a consultant for, is on the speakers' bureau of, and received grants from Roche. He advises and received grants from Vertex. He received grants from Schering-Plough and March. Dr. Shiffman advises and received grants from Biolex, Conatus, Human Genome Sciences, Romark, Valeant, Vertex, and Zymogenetics. He advises Bristol-Myers Squibb, Anadys and Novartis. He received grants from GlaxoSmithKline, Globeimmune, Idenix, Johnson and Johnson, and Wyeth. He is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. He also advises, is on the speakers' bureau of, and received grants from Schering-Plough. Dr. Stoddard owns stock in Elan Corp., Johnson and Johnson, Stryker, Proctor and Gamble, and Bristol-Myers Squibb.

  3. §

    Additional support was provided by Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement with the National Institutes of Health. (See †† for contract and grant details.)

Publication History

  1. Issue published online: 20 NOV 2009
  2. Article first published online: 5 AUG 2009
  3. Accepted manuscript online: 5 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 28 JUL 2009
  5. Manuscript Received: 22 APR 2009

Funded by

  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • National Center for Minority Health and Health Disparities
  • General Clinical Research Center
  • Clinical and Translational Science Center grants from the National Center for Research Resources
  • National Institutes of Health

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1037K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    P. Calès, J. P. Zarski, J. Marc Chapplain, S. Bertrais, N. Sturm, C. Michelet, G. Babany, J. Chaigneau, M. Eddine Charaf, Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry, Journal of Viral Hepatitis, 2012, 19, 2
    Direct Link:
  2. 2
    Pierre Bedossa, Valerie Paradis, MacSween's Pathology of the Liver, 2012,

    CrossRef

  3. 3
    Massimo Sartori, Silvano Andorno, Angelo Rossini, Renzo Boldorini, Cristina Bozzola, Stefania Carmagnola, Mario Del Piano, Emanuele Albano, A case–control histological study on the effects of phlebotomy in patients with chronic hepatitis C, European Journal of Gastroenterology & Hepatology, 2011, 23, 12, 1178

    CrossRef

  4. 4
    Indra Neil Guha, Robert P. Myers, Keyur Patel, Jayant A. Talwalkar, Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?, Hepatology, 2011, 54, 4
    Direct Link:
  5. 5
    S. C. Raftopoulos, J. George, M. Bourliere, E. Rossi, W. B. Boer, G. P. Jeffrey, M. Bulsara, D. J. Speers, G. MacQuillan, H. L. I. Ching, N. Kontorinis, W. Cheng, J. Flexman, S. Fermoyle, P. Rigby, L. Walsh, D. McLeod, L. A. Adams, Comparison of noninvasive models of fibrosis in chronic hepatitis B, Hepatology International, 2011, 6, 2, 457

    CrossRef

  6. 6
    Hiroyuki Ishibashi, Hitoshi Maruyama, Masanori Takahashi, Taro Shimada, Hidehiro Kamesaki, Keiichi Fujiwara, Fumio Imazeki, Osamu Yokosuka, Demonstration of intrahepatic accumulated microbubble on ultrasound represents the grade of hepatic fibrosis, European Radiology, 2011, 22, 5, 1083

    CrossRef

  7. 7
    Pinelopi Manousou, Amar P. Dhillon, Graziela Isgro, Vincenza Calvaruso, T.V. Luong, Emmanuel Tsochatzis, E. Xirouchakis, G. Kalambokis, Timothy J. Cross, N. Rolando, James O'Beirne, David Patch, D. Thornburn, Andrew K. Burroughs, Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation, Liver Transplantation, 2011, 17, 2
    Direct Link:
  8. 8
    John C. Hoefs, Mitchell L. Shiffman, Zachary D. Goodman, David E. Kleiner, Jules L. Dienstag, Anne M. Stoddard, Rate of Progression of Hepatic Fibrosis in Patients With Chronic Hepatitis C: Results From the HALT-C Trial, Gastroenterology, 2011, 141, 3, 900

    CrossRef

  9. You have free access to this content9
    N. D. Freedman, T. M. Curto, C. Morishima, L. B. Seeff, Z. D. Goodman, E. C. Wright, R. Sinha, J. E. Everhart, Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial, Alimentary Pharmacology & Therapeutics, 2011, 33, 1
    Direct Link:
  10. 10
    Marcin Krawczyk, Frank Grünhage, Vincent Zimmer, Frank Lammert, Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease, Journal of Hepatology, 2011, 55, 2, 299

    CrossRef

  11. 11
    Scott L. Friedman, Evolving challenges in hepatic fibrosis, Nature Reviews Gastroenterology & Hepatology, 2010, 7, 8, 425

    CrossRef

  12. 12
    Keyur Patel, Noninvasive tools to assess liver disease, Current Opinion in Gastroenterology, 2010, 26, 3, 227

    CrossRef

  13. 13
    M. Isabel Fiel, Pathology of Chronic Hepatitis B and Chronic Hepatitis C, Clinics in Liver Disease, 2010, 14, 4, 555

    CrossRef

View Full Article (HTML) Get PDF (1037K)